WCN26-2876 Effects of Non-steroidal Mineralocorticoid Receptor Blocker Esaxerenone on Glomerular Hemodynamics in type 2 Diabetic Kidney Disease

Read full text Summarise with VIRAT
Authors: Rie Tatsugawa, Kengo Kidokoro, Yoshihisa Wada, Tsukasa Iwakura, Masafumi Wada, Masanobu Takasu, Akira Hirano, Kitao Hiroshi, Hajime Nagasu, Tamaki Sasaki, Naoki Kashihara
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The non-steroidal selective mineralocorticoid receptor blocker (nsMRB) finerenone has demonstrated renoprotective effects in patients with type 2 diabetes and chronic kidney disease (CKD) (FIDELIO-DKD study). Similarly, the nsMRB esaxerenone (Esax) significantly reduced albuminuria compared with placebo in a phase III trial involving early diabetic kidney disease (DKD), suggesting renoprotective effects comparable to finerenone (ESAX-DN study). However, the molecular mechanisms underlying the renoprotective and albuminuria-lowering effects of nsMRBs remain unclear.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Hormonal Regulation and Hypertension Renal Diseases and Glomerulopathies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104598–104598
Publication date
25 March 2026
Language
EN